228 related articles for article (PubMed ID: 11555579)
1. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
3. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Go RS; Horstman AL
Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
[No Abstract] [Full Text] [Related]
4. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
5. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
6. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
7. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
[TBL] [Abstract][Full Text] [Related]
10. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
12. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
[TBL] [Abstract][Full Text] [Related]
13. [Thalidomide for the treatment of refractory multiple myeloma].
Kakimoto T; Hattori Y; Okamoto S
Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
[No Abstract] [Full Text] [Related]
14. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
16. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
19. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
20. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
